Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome-a clinical pilot study.

ABSTRACT:

Background

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent need for elucidation of disease mechanisms and for rational treatment. Our working hypothesis is that ME/CFS in a subgroup of patients is associated with functional autoantibodies emerging after an infection, and that plasma-cell depletion with transient reductions in serum immunoglobulins will have a beneficial effect on patients' symptoms.

Objective

To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12-24 months follow-up after daratumumab interventi

SUBMITTER: Fluge O 

PROVIDER: S-EPMC12283730 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature